We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Resistance Training in Lung Cancer Patients on Chemotherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01130714
Recruitment Status : Completed
First Posted : May 26, 2010
Last Update Posted : August 20, 2015
Information provided by (Responsible Party):
Kristina Karvinen, East Carolina University

Brief Summary:
The purpose of this study is to examine the effectiveness of a resistance training program on reducing systemic inflammation and improving chemotherapy completion in lung cancer patients being treated with curative intent chemotherapy.

Condition or disease Intervention/treatment
Inflammation Lung Cancer Behavioral: Exercise

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Effectiveness of a Resistance Training Program on Inflammatory Markers and Chemotherapy Completion in Lung Cancer Patients on Chemotherapy
Study Start Date : January 2010
Primary Completion Date : July 2012
Study Completion Date : July 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Resistance training
Group assigned to complete resistance training during duration of chemotherapy.
Behavioral: Exercise
Resistance training with resistance bands.
No Intervention: Control
Usual care.

Primary Outcome Measures :
  1. Systemic inflammation measured by c-reactive protein. [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Chemotherapy completion [ Time Frame: 12 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically diagnosed with lung cancer
  • Stage I, II, or III
  • Eligible for chemotherapy with curative intent
  • 21 years of age or older
  • Approval to participate in study by treating oncologist or family physician

Exclusion Criteria:

  • Unstable cardiac disease
  • Untreated bone or brain metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01130714

United States, North Carolina
Leo Jenkins Cancer Center
Greenville, North Carolina, United States, 27834
Sponsors and Collaborators
East Carolina University
Principal Investigator: Kristina H Karvinen, PhD East Carolina University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Kristina Karvinen, Assistant Professor, East Carolina University
ClinicalTrials.gov Identifier: NCT01130714     History of Changes
Other Study ID Numbers: UMCIRB 09-0725
First Posted: May 26, 2010    Key Record Dates
Last Update Posted: August 20, 2015
Last Verified: August 2015

Keywords provided by Kristina Karvinen, East Carolina University:
lung cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Pathologic Processes